Arch Therapeutics, Inc.
OTC: ARTH0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Terrence W. Norchi
- Employees
- 8
- Headquarters
- Framingham, United States
- IPO year
- 2013
- Market cap
- $444.0
- Website
- https://www.archtherapeutics.com
Loading ARTH…
Loading profile data…Frequently asked questions about ARTH
What does Arch Therapeutics, Inc. (ARTH) do?
Arch Therapeutics, Inc., operating alongside its affiliated companies, functions as a biotechnology firm within the United States. The organization focuses on developing and commercializing products derived from its unique AC5 self-assembling technology platform. These innovations are engineered to arrest bleeding, control fluid leakage, and ass...
Where does ARTH trade?
Arch Therapeutics, Inc. (ARTH) trades on the Other OTC.
What sector is ARTH in?
Arch Therapeutics, Inc. (ARTH) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Arch Therapeutics, Inc.?
Terrence W. Norchi is the chief executive officer of Arch Therapeutics, Inc. (ARTH).
Where is Arch Therapeutics, Inc. headquartered?
Arch Therapeutics, Inc. is headquartered in United States.
Does ARTH pay a dividend?
Arch Therapeutics, Inc. (ARTH) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ARTH go public?
Arch Therapeutics, Inc. (ARTH) completed its initial public offering in 2013.